| Literature DB >> 27168934 |
Abilash Nair1, Randeep Guleria2, Devasenathipathy Kandasamy3, Raju Sharma3, Nikhil Tandon1, Urvashi B Singh4, Ravinder Goswami1.
Abstract
BACKGROUND: There is limited information on prevalence of pulmonary tuberculosis (PTB) in patients with type-1-diabetes. We assessed the prevalence of PTB in patients with type-1-diabetes attending the outpatient-clinic in a tertiary-care hospital.Entities:
Keywords: HbA1c; Tuberculosis; Type1 Diabetes
Year: 2016 PMID: 27168934 PMCID: PMC4862037 DOI: 10.1186/s40248-016-0058-z
Source DB: PubMed Journal: Multidiscip Respir Med ISSN: 1828-695X
Fig. 1Flow of patients in the study
Clinical findings of 25 patients screened for sputum M.tb positivity and their follow up in the pulmonology clinic
| S N | Age/Sex | Findings at initial screening | Follow up in the Pulmonology clinic | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Indication for screening by sputum | Sputum culture | ESR | TST | Symptom | Radiograph | Sputum culture M.Tb | ATT | |||||
| History | Radiography | Ist | 2nd | Ist | 2nd | |||||||
| 1 | 40,M | Wt loss, Past TB | Lt upper lobe Cavity | +ve | +ve | 40 | 11 | None | No change | -ve | +ve | Yes |
| 2 | 25,F | Cough > 2 weeks & Past TB | Lt upper lobe fibrocavitory consolidation | +ve | +ve | 30 | 11 | Hemoptysis | No change | -ve | +ve | Yes |
| 3 | 36,F | Past TB | Lt upper lobe Consolidation | +ve | +ve | 37 | 11 | Wt loss | No change | -ve | -ve | Yes |
| 4 | 28,F | None | Rt hilar adenopathy | +ve | -ve | 8 | 5 | None | No change | -ve | +ve | Yes |
| 5 | 25,F | Past TB | Normal | +ve | -ve | 38 | 10 | Fever > 2 weeks | Normal | -ve | +ve | Yes |
| 6 | 22,F | Past TB | Normal | -ve | +ve | 118 | 5 | Pericardial effusion | Pericardial effusion | ND | ND | Yes |
| 7 | 28,F | Past TB | Rt pleural thickening | +ve | +ve | 15 | 9 | None | No change | -ve | +ve | Yes |
| 8 | 47,F | Past TB | Rt bronchiectasis | +ve | SNA | 26 | 10 | None | No change | -ve | +ve | Yes |
| 9 | 65,F | Past TB | Lt upper lobe Fibrosis | +ve | -ve | 20 | 8 | None | No change | -ve | -ve | No |
| 10 | 39,M | Past TB | Normal | SNA | -ve | 10 | 8 | None | Expired | No | ||
| 11 | 37,F | Past TB | Normal | +ve | SNA | 5 | 0 | None | Normal | -ve | -ve | No |
| 12 | 40,F | Past TB | Rt lower lobe fibrosis | -ve | +ve | 5 | 6 | None | Normal | -ve | -ve | No |
| 13 | 46, M | Past TB | Normal | +ve | -ve | 30 | 4 | None | Normal | -ve | -ve | No |
| 14 | 36,M | Past TB | Normal | +ve | SNA | 15 | 0 | None | Normal | -ve | -ve | No |
| 15 | 32,M | Past TB | Normal | +ve | +ve | 10 | 2 | None | Normal | -ve | -ve | No |
| 16 | 40,M | Past TB | Normal | -ve | +ve | 10 | 0 | None | Normal | -ve | -ve | No |
| 17 | 22,M | Cough > 2 weeks | Normal | -ve | -ve | 3 | 6 | None | NR | NR | NR | No |
| 18 | 43,M | Past TB | Rt upper lobe fibrosis & Lt lower lobe calcification | -ve | -ve | 5 | 10 | None | NR | NR | NR | No |
| 19 | 34,F | Past TB | Normal | -ve | -ve | 16 | 5 | None | NR | NR | NR | No |
| 20 | 23,F | Past TB | Normal | -ve | -ve | 10 | 4 | None | NR | NR | NR | No |
| 21 | 38, M | Past TB | Normal | -ve | -ve | 8 | 0 | None | NR | NR | NR | No |
| 22 | 20,M | Past TB | Normal | -ve | -ve | 10 | 10 | None | NR | NR | NR | No |
| 23 | 38,M | Past TB | Normal | -ve | -ve | 5 | 12 | None | NR | NR | NR | No |
| 24 | 30,F | Past TB | Normal | -ve | -ve | 48 | 0 | None | NR | NR | NR | No |
| 25 | 28,F | Past TB | Rt pleural thickening | -ve | -ve | 3 | 0 | None | NR | NR | NR | No |
M male, F female, Lt left, Rt right, TB tuberculosis, wt weight, SNA sample not available, ND not done, NR not required
Baseline characteristics in patients with and without positive sputum M.tb culture
| Parameters | Sputum |
| |
|---|---|---|---|
| Negative | Positive | ||
| ( | ( | ||
| Male: Female (n) | 65:70 | 10:6 | 0.59 |
| Age (years) | 27.1 ± 10.87 | 36.9 ± 10.5 | <0.001 |
| Body mass index (kg/m2) | 20.8 ± 3.78 | 20.9 ± 3.36 | 0.89 |
| Duration of diabetes (years) | 12.5 ± 7.46 | 18.9 ± 5.38 | <0.01 |
| Retinopathy (n) | 22 (16.29 %) | 11(68.75 %) | <0.001 |
| Proteinuria(urine protein >150 mg/24 h) | 18 (13.33 %) | 4 (25.0 %) | 0.22 |
| Chronic kidney disease (eGFR <60 ml/min)(n) | 8 (5.5 %) | 5 (31.2 %) | <0.001 |
| Current HbA1c (%) | 9.1 ± 2.1 | 8.1 ± 1.7 | 0.10 |
| Pooled HbA1c during (%) | 9.1 ± 1.8 | 8.4 ± 1.7 | 0.19 |
| Serum total cholesterol (mg/dL) | 165.8 ± 36.68 | 171.8 ± 32.75 | 0.53 |
| Serum triglycerides (mg/dL) | 98.3 ± 54.58 | 107.7 ± 47.42 | 0.51 |
| Serum LDL (mg/dL) | 93.2 ± 28.98 | 97.9 ± 27.32 | 0.53 |
| Serum HDL (mg/dL) | 54.1 ± 19.28 | 51.3 ± 14.47 | 0.58 |
| Hemoglobin (g/dl) | 12.7 ± 2.04 | 12.8 ± 1.65 | 0.90 |
| Total leukocytes count/mm3) | 7360 ± 1889 | 8069 ± 1695 | 0.15 |
| Polymorphs (%) | 59.4 ± 9.75 | 61.1 ± 9.66 | 0.52 |
| Lymphocyte (%) | 30 ± 8.1 | 28 ± 9.1 | 0.20 |
| Erythrocyte sedimentation rate (mm/h) | 17.0 ± 13.62 | 27.1 ± 26.80 | <0.001 |
| Elevated ESR ( | 50 (38.2 % | 10 (62.5 % | 0.06 |
| Mantoux (>10 mm) ( | 13 (10.07 %) | 5 (31.25 %) | 0.02 |